Efficacy of conbercept after switching from bevacizumab/ranibizumab in eyes of macular edema secondary to central retinal vein occlusion

To explore the efficacy of conbercept after switching from bevacizumab/ranibizumab in eyes of central retinal vein occlusion (CRVO) through optical coherence tomography angiography (OCTA). Patients with prior treatment of a minimum of three consecutive intravitreal injections of either bevacizumab o...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of ophthalmology Vol. 15; no. 4; pp. 609 - 614
Main Authors Zhao, Tong, Chen, You, Zhang, Hong-Song, Chen, Yi, Wang, Zhi-Jun
Format Journal Article
LanguageEnglish
Published China International Journal of Ophthalmology Press 18.04.2022
Press of International Journal of Ophthalmology (IJO PRESS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To explore the efficacy of conbercept after switching from bevacizumab/ranibizumab in eyes of central retinal vein occlusion (CRVO) through optical coherence tomography angiography (OCTA). Patients with prior treatment of a minimum of three consecutive intravitreal injections of either bevacizumab or ranibizumab, followed by injection of conbercept, were recruited. The minimal follow-up period after switching was 12mo. Central retinal thickness (CRT), best-corrected visual acuity (BCVA), the interval of injections was reviewed. Perfusion density (PD) and vascular length density (VLD) of superficial and deep capillary plexus were acquired from OCTA images before and after switching. Twenty-four eyes were included. CRT significantly decreased from 460.71±153.23 µm (before switching) to 283.92±38.27 µm at the end of follow-up ( <0.001). However, BCVA gained to some extent (from 0.98±0.33 to 0.76±0.42 logMAR) but the difference was not significant ( =0.070). After switching to conbercept the injection interval extended from 5.2±2.3wk to 8.3±3.9wk ( =0.012). At the end of follow-up, PD of deep retinal layer decreased significantly compared with before switching (from 34.62%±5.27% to 33.26%±5.82%, =0.016), similar result was found in VLD of deep retinal layer but not in PD or VLD in superficial layer. In cases of refractory macular edema secondary to CRVO, switching to conbercept improves macular thickness and extends interval of injection. Retinal microvasculature cannot improve with treatment of conbercept.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2222-3959
2227-4898
DOI:10.18240/ijo.2022.04.14